Ocular Therapeutix Stock Forecast, Price & News

Ocular Therapeutix (NASDAQ:OCUL) Frequently Asked Questions

Is Ocular Therapeutix a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Ocular Therapeutix stock.
View analyst ratings for Ocular Therapeutix or view top-rated stocks.

How has Ocular Therapeutix's stock price been impacted by Coronavirus?

Ocular Therapeutix's stock was trading at $5.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, OCUL shares have increased by 9.7% and is now trading at $5.87.
View which stocks have been most impacted by COVID-19.

When is Ocular Therapeutix's next earnings date?

Ocular Therapeutix is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Ocular Therapeutix.

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) posted its quarterly earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.03. The biopharmaceutical company earned $12.15 million during the quarter, compared to the consensus estimate of $12.13 million. Ocular Therapeutix had a negative net margin of 229.02% and a negative trailing twelve-month return on equity of 22.95%. During the same period in the prior year, the firm posted ($0.17) EPS.
View Ocular Therapeutix's earnings history.

What price target have analysts set for OCUL?

4 brokerages have issued 12-month target prices for Ocular Therapeutix's stock. Their forecasts range from $14.00 to $30.00. On average, they expect Ocular Therapeutix's share price to reach $23.25 in the next twelve months. This suggests a possible upside of 296.1% from the stock's current price.
View analysts' price targets for Ocular Therapeutix or view top-rated stocks among Wall Street analysts.

Who are Ocular Therapeutix's key executives?

Ocular Therapeutix's management team includes the following people:

• Antony Mattessich, President, Chief Executive Officer & Director (LinkedIn Profile)
• Donald Notman, Chief Financial Officer
• Peter Jarrett, Chief Scientific Officer
• Michael H. Goldstein, Chief Medical Officer & Ophthalmology President
• Rabia Gurses Ozden, Senior Vice President-Clinical Development

Who are some of Ocular Therapeutix's key competitors?

Some companies that are related to Ocular Therapeutix include Taro Pharmaceutical Industries (TARO), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), Agios Pharmaceuticals (AGIO), Prothena (PRTA), Cassava Sciences (SAVA), Protagonist Therapeutics (PTGX), Xenon Pharmaceuticals (XENE), Verve Therapeutics (VERV), Travere Therapeutics (TVTX), Dynavax Technologies (DVAX), Supernus Pharmaceuticals (SUPN), IVERIC bio (ISEE), Morphic (MORF) and Zogenix (ZGNX).
View all of OCUL's competitors.

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), (CELG), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

Who are Ocular Therapeutix's major shareholders?

Ocular Therapeutix's stock is owned by a number of institutional and retail investors. Top institutional investors include Vigilare Wealth Management (0.03%) and Hikari Power Ltd (0.02%). Company insiders that own Ocular Therapeutix stock include Antony C Mattessich, Richard L Md Lindstrom and Summer Road Llc.
View institutional ownership trends for Ocular Therapeutix.

Which institutional investors are selling Ocular Therapeutix stock?

OCUL stock was sold by a variety of institutional investors in the last quarter, including Vigilare Wealth Management.
View insider buying and selling activity for Ocular Therapeutix or view top insider-selling stocks.

Which institutional investors are buying Ocular Therapeutix stock?

OCUL stock was acquired by a variety of institutional investors in the last quarter, including Hikari Power Ltd. Company insiders that have bought Ocular Therapeutix stock in the last two years include Antony C Mattessich, and Summer Road Llc.
View insider buying and selling activity for Ocular Therapeutix or or view top insider-buying stocks.

How do I buy shares of Ocular Therapeutix?

Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ocular Therapeutix's stock price today?

One share of OCUL stock can currently be purchased for approximately $5.87.

How much money does Ocular Therapeutix make?

Ocular Therapeutix has a market capitalization of $449.70 million and generates $17.40 million in revenue each year. The biopharmaceutical company earns $-155.64 million in net income (profit) each year or ($1.93) on an earnings per share basis.

How many employees does Ocular Therapeutix have?

Ocular Therapeutix employs 181 workers across the globe.

What is Ocular Therapeutix's official website?

The official website for Ocular Therapeutix is www.ocutx.com.

Where are Ocular Therapeutix's headquarters?

Ocular Therapeutix is headquartered at 15 CROSBY DRIVE, BEDFORD MA, 01730.

How can I contact Ocular Therapeutix?

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at (781) 357-4000, via email at [email protected], or via fax at 781-357-4001.